The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis-Reference-Cited by-同舟云学术

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis

Published:2022-10-13 Issue: Volume: Page:
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Alten Rieke^ORCID,Burmester Gerd R.,Matucci-Cerinic Marco,Salmon Jean-Hugues,Lopez-Romero Pedro,Fakhouri Walid,de la Torre Inmaculada,Zaremba-Pechmann Liliana,Holzkämper Thorsten,Fautrel Bruno

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-022-00500-6.pdf

Reference32 articles.

1. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72. https://doi.org/10.1001/jama.2018.13103.

2. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655.

3. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39. https://doi.org/10.1002/acr.24596.